

Supplementary Tables

Supplementary Table 1a: Percentage Inhibition of classical pathway activity by C1-INH in combination with heparin, dalteparin, nadroparin or enoxaparin. The inhibition of C5b-9 deposition was calculated by dividing the OD of the sample with heparinoid by the control, the sample without heparinoid or C1-INH. Data are expressed in the mean and SEM of n = 3 experiments.

Heparinoids	C1-Inhibitor:					
	0 U/mL	0.375 U/mL	0.75 U/mL	1.5 U/mL	3 U/mL	6 U/mL
0 UI/mL	0%	69.4% ± 2.5%	79.3% ± 2.0%	86.2% ± 1.6%	91.6% ± 1.2%	96.3% ± 0.4%
Heparin:						
0.0625 UI/mL	54.1% ± 3.7%	77.5% ± 1.8%	85.2% ± 1.1%	88.9% ± 0.6%	91.5% ± 0.5%	91.5% ± 3.9%
0.125 UI/mL	31.9% ± 5.2%	81.0% ± 1.4%	87.2% ± 0.9%	91.9% ± 0.6%	94.8% ± 0.4%	97.9% ± 0.2%
0.25 UI/mL	44.8% ± 5.2%	83.2% ± 1.5%	86.5% ± 1.3%	92.5% ± 0.6%	96.4% ± 0.3%	98.2% ± 0.1%
0.5 UI/mL	64.1% ± 2.5%	90.0% ± 1.0%	94.0% ± 1.0%	96.8% ± 0.5%	98.3% ± 0.3%	99.6% ± 0.1%
1.0 UI/mL	60.4% ± 3.0%	93.1% ± 0.6%	96.2% ± 0.3%	98.2% ± 0.2%	99.0% ± 0.2%	99.2% ± 0.1%
Dalteparin :						
0.0625 UI/mL	28.6% ± 6.0%	80.4% ± 2.1%	86.6% ± 1.5%	91.7% ± 0.8%	95.5% ± 0.3%	97.8% ± 0.1%
0.125 UI/mL	40.7% ± 4.7%	83.3% ± 1.4%	86.1% ± 0.9%	92.6% ± 0.9%	95.9% ± 0.5%	98.6% ± 0.1%
0.25 UI/mL	46.0% ± 4.2%	88.2% ± 1.0%	93.4% ± 0.8%	96.4% ± 0.3%	98.3% ± 0.3%	99.5% ± 0.1%
0.5 UI/mL	60.0% ± 2.8%	92.3% ± 0.8%	95.5% ± 0.3%	97.7% ± 0.2%	99.1% ± 0.1%	99.2% ± 0.2%
1.0 UI/mL	42.2% ± 1.9%	92.2% ± 0.2%	95.2% ± 0.1%	97.1% ± 0.1%	99.2% ± 0.1%	99.4% ± 0.5%
Nadroparin:						
0.0625 UI/mL	10.9% ± 6.2%	75.4% ± 2.2%	85.7% ± 1.4%	89.8% ± 1.1%	94.2% ± 0.7%	97.6% ± 0.4%
0.125 UI/mL	23.5% ± 4.6%	76.7% ± 1.3%	82.7% ± 1.0%	88.4% ± 0.8%	94.1% ± 0.4%	96.9% ± 0.4%
0.25 UI/mL	15.9% ± 6.3%	79.4% ± 2.9%	85.6% ± 2.0%	89.0% ± 2.4%	95.2% ± 0.4%	98.1% ± 0.2%
0.5 UI/mL	43.8% ± 5.3%	86.4% ± 1.9%	89.3% ± 1.2%	94.0% ± 0.6%	96.7% ± 0.6%	98.8% ± 0.2%
1.0 UI/mL	42.5% ± 5.3%	90.2% ± 0.8%	94.9% ± 0.6%	97.2% ± 0.4%	99.0% ± 0.2%	99.6% ± 0.1%
Enoxaparin:						
0.0625 UI/mL	21.0% ± 5.2%	68.1% ± 2.5%	73.4% ± 2.0%	83.5% ± 1.6%	91.0% ± 1.2%	95.7% ± 0.4%
0.125 UI/mL	20.6% ± 4.1%	77.5% ± 2.4%	85.1% ± 1.2%	90.7% ± 1.0%	94.6% ± 0.8%	97.0% ± 0.3%
0.25 UI/mL	21.6% ± 3.8%	80.0% ± 1.2%	86.1% ± 1.0%	90.6% ± 0.6%	96.0% ± 0.2%	97.1% ± 0.2%
0.5 UI/mL	21.5% ± 4.8%	80.5% ± 1.7%	84.2% ± 1.1%	91.1% ± 0.5%	96.2% ± 0.3%	98.6% ± 0.2%
1.0 UI/mL	41.2% ± 4.0%	87.8% ± 0.9%	92.0% ± 0.5%	96.1% ± 0.3%	98.7% ± 0.2%	99.5% ± 0.1%

F. Poppelaars

Supplementary Table 1b: Percentage Inhibition of lectin pathway activity by C1-INH in combination with heparin, dalteparin, nadroparin or enoxaparin. The inhibition of C5b-9 deposition was calculated by dividing the OD of the sample with heparinoid by the control, the sample without heparinoid or C1-INH. Data are expressed in the mean and SEM of n = 3 experiments.

Heparinoids	C1-Inhibitor:					
	<i>0 U/mL</i>	<i>0.375 U/mL</i>	<i>0.75 U/mL</i>	<i>1.5 U/mL</i>	<i>3 U/mL</i>	<i>6 U/mL</i>
<i>0 UI/mL</i>	0%	95.5% ± 0.1%	99.1% ± 0.1%	99.5% ± 0.1%	99.7% ± 0.2%	99.9% ± 0.1%
Heparin:						
<i>0.0625 UI/mL</i>	44.4% ± 1.4%	97.1% ± 0.1%	98.9% ± 0.0%	99.6% ± 0.1%	100.0% ± 0.1%	99.8% ± 0.1%
<i>0.125 UI/mL</i>	62.8% ± 0.3%	97.7% ± 0.1%	99.2% ± 0.1%	99.3% ± 0.1%	99.8% ± 0.1%	100.0% ± 0.1%
<i>0.25 UI/mL</i>	81.7% ± 0.2%	97.5% ± 0.2%	98.7% ± 0.3%	99.6% ± 0.1%	99.2% ± 0.1%	99.4% ± 0.1%
<i>0.5 UI/mL</i>	90.1% ± 0.2%	100.0% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.1%	100.0% ± 0.0%
<i>1.0 UI/mL</i>	85.6% ± 0.9%	100.0% ± 0.0%	100.0% ± 0.1%	100.0% ± 0.0%	100.0% ± 0.1%	100.0% ± 0.0%
Dalteparin :						
<i>0.0625 UI/mL</i>	61.9% ± 0.6%	98.8% ± 0.1%	99.8% ± 0.0%	100.0% ± 0.0%	99.8% ± 0.0%	100.0% ± 0.0%
<i>0.125 UI/mL</i>	76.8% ± 1.9%	98.3% ± 0.1%	99.6% ± 0.1%	100.0% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%
<i>0.25 UI/mL</i>	79.4% ± 0.7%	100.0% ± 0.0%	100.0% ± 0.1%	100.0% ± 0.1%	100.0% ± 0.1%	100.0% ± 0.1%
<i>0.5 UI/mL</i>	89.2% ± 0.5%	99.9% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.2%	100.0% ± 0.1%
<i>1.0 UI/mL</i>	91.3% ± 0.4%	99.9% ± 0.0%	100.0% ± 0.1%	100.0% ± 0.0%	100.0% ± 0.1%	100.0% ± 0.0%
Nadroparin:						
<i>0.0625 UI/mL</i>	38.6% ± 1.3%	97.5% ± 0.0%	99.4% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%
<i>0.125 UI/mL</i>	61.0% ± 0.3%	97.3% ± 0.0%	99.3% ± 0.1%	99.9% ± 0.0%	100.0% ± 0.0%	99.8% ± 0.0%
<i>0.25 UI/mL</i>	69.7% ± 0.8%	98.9% ± 0.0%	99.9% ± 0.0%	100.0% ± 0.0%	99.8% ± 0.0%	100.0% ± 0.0%
<i>0.5 UI/mL</i>	84.4% ± 0.9%	99.6% ± 0.0%	99.7% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%
<i>1.0 UI/mL</i>	87.6% ± 0.3%	100.0% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%	99.9% ± 0.1%	100.0% ± 0.0%
Enoxaparin:						
<i>0.0625 UI/mL</i>	39.8% ± 1.3%	95.5% ± 0.3%	99.3% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.1%	100.0% ± 0.1%
<i>0.125 UI/mL</i>	52.4% ± 1.7%	98.2% ± 0.0%	99.8% ± 0.0%	99.8% ± 0.1%	100.0% ± 0.0%	100.0% ± 0.0%
<i>0.25 UI/mL</i>	66.4% ± 0.2%	98.9% ± 0.1%	99.8% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%
<i>0.5 UI/mL</i>	77.2% ± 0.3%	99.4% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%
<i>1.0 UI/mL</i>	89.2% ± 0.3%	99.6% ± 0.0%	99.8% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%	100.0% ± 0.0%

Supplementary Table 1c: Percentage Inhibition of alternative pathway activity by C1-INH in combination with heparin, dalteparin, nadroparin or enoxaparin. The inhibition of C5b-9 deposition was calculated by dividing the OD of the sample with heparinoid by the control, the sample without heparinoid or C1-INH. Data are expressed in the mean and SEM of n = 3 experiments.

Heparinoids	C1-Inhibitor:					
	<i>0 U/mL</i>	<i>0.375 U/mL</i>	<i>0.75 U/mL</i>	<i>1.5 U/mL</i>	<i>3 U/mL</i>	<i>6 U/mL</i>
<i>0 UI/mL</i>	0%	37.6% ± 3.3%	57.8% ± 2.4%	60.0% ± 2.7%	65.0% ± 2.6%	85.2% ± 1.0%
Heparin:						
<i>0.0625 UI/mL</i>	0.8% ± 4.4%	14.0% ± 2.5%	19.8% ± 1.6%	16.8% ± 1.8%	26.8% ± 1.9%	50.1% ± 3.0%
<i>0.125 UI/mL</i>	24.6% ± 5.7%	40.2% ± 1.8%	40.5% ± 4.1%	27.3% ± 0.4%	31.0% ± 1.7%	78.9% ± 0.1%
<i>0.25 UI/mL</i>	61.0% ± 1.7%	47.4% ± 1.8%	0.0% ± 3.5%	34.2% ± 2.3%	65.0% ± 0.5%	85.6% ± 1.0%
<i>0.5 UI/mL</i>	53.1% ± 4.4%	74.1% ± 3.1%	88.5% ± 0.8%	91.8% ± 0.9%	93.8% ± 0.5%	96.7% ± 0.4%
<i>1.0 UI/mL</i>	68.4% ± 1.7%	77.8% ± 1.4%	78.6% ± 0.9%	80.3% ± 0.7%	77.9% ± 0.2%	75.9% ± 0.3%
Dalteparin :						
<i>0.0625 UI/mL</i>	22.2% ± 1.7%	37.4% ± 2.4%	40.7% ± 3.9%	39.5% ± 4.1%	56.3% ± 1.6%	87.5% ± 0.7%
<i>0.125 UI/mL</i>	82.4% ± 2.3%	77.1% ± 1.1%	0.8% ± 2.4%	36.4% ± 0.7%	67.6% ± 0.6%	88.1% ± 0.2%
<i>0.25 UI/mL</i>	23.1% ± 0.8%	28.8% ± 1.8%	29.8% ± 1.7%	31.4% ± 0.9%	32.0% ± 0.5%	32.8% ± 0.2%
<i>0.5 UI/mL</i>	84.2% ± 1.2%	88.3% ± 1.1%	91.1% ± 0.7%	90.9% ± 0.4%	92.0% ± 0.5%	92.7% ± 0.3%
<i>1.0 UI/mL</i>	72.6% ± 1.1%	73.5% ± 1.3%	61.8% ± 1.2%	51.8% ± 2.5%	90.6% ± 0.3%	98.0% ± 0.2%
Nadroparin:						
<i>0.0625 UI/mL</i>	43.3% ± 1.0%	73.9% ± 1.2%	83.8% ± 0.8%	90.7% ± 0.6%	92.9% ± 0.5%	97.0% ± 0.2%
<i>0.125 UI/mL</i>	59.5% ± 4.2%	74.4% ± 2.4%	61.5% ± 1.1%	68.7% ± 1.8%	80.0% ± 0.8%	75.3% ± 0.7%
<i>0.25 UI/mL</i>	40.7% ± 0.2%	51.5% ± 1.8%	49.8% ± 0.9%	32.7% ± 3.1%	55.8% ± 2.9%	89.0% ± 1.0%
<i>0.5 UI/mL</i>	82.6% ± 1.2%	65.9% ± 2.1%	8.3% ± 2.1%	44.9% ± 1.1%	65.3% ± 0.9%	86.7% ± 0.6%
<i>1.0 UI/mL</i>	62.8% ± 0.7%	84.0% ± 1.2%	91.5% ± 1.0%	94.8% ± 0.6%	96.8% ± 0.3%	98.0% ± 0.2%
Enoxaparin:						
<i>0.0625 UI/mL</i>	38.0% ± 1.6%	21.5% ± 3.5%	32.9% ± 1.9%	54.8% ± 0.9%	67.3% ± 1.1%	81.7% ± 0.4%
<i>0.125 UI/mL</i>	44.3% ± 2.4%	70.5% ± 2.7%	80.9% ± 1.9%	83.6% ± 1.3%	90.7% ± 0.6%	94.2% ± 0.4%
<i>0.25 UI/mL</i>	22.1% ± 7.0%	49.6% ± 4.2%	44.2% ± 6.2%	55.7% ± 4.9%	54.9% ± 4.1%	67.2% ± 2.1%
<i>0.5 UI/mL</i>	42.5% ± 1.8%	35.2% ± 4.5%	38.0% ± 1.8%	22.5% ± 3.2%	42.5% ± 4.2%	85.3% ± 1.1%
<i>1.0 UI/mL</i>	88.1% ± 0.6%	73.7% ± 0.9%	43.3% ± 2.7%	62.0% ± 1.8%	75.8% ± 1.1%	91.7% ± 0.4%